{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The Food and Drug Administration said yesterday that it had received reports of partial vision loss in 38 men taking Viagra, the impotence drug, and among 4 men taking Cialis, a newer competitor. The F.D.A. has asked Pfizer, the maker of Viagra, to add a note to the drug's label so that patients are aware of the possible link. The makers of Cialis -- Eli Lilly & Company and the Icos Corporation -- have already made such a change.", "headline": {"main": "Vision Loss Is Reported In a Few Users Of Viagra"}, "abstract": null, "print_page": "1", "word_count": 618, "_id": "4fd247908eb7c8105d7e3978", "snippet": "The F.D.A. said Friday that it had received reports of partial vision loss in 38 men taking Viagra and among 4 men taking Cialis, a newer competitor.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/05/28/business/28viagra.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "ELI LILLY AND COMPANY"}, {"name": "organizations", "value": "PFIZER INCORPORATED"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Alex", "rank": 1, "lastname": "BERENSON"}, {"organization": "", "role": "reported", "firstname": "Jennifer", "rank": 2, "lastname": "BAYOT"}], "original": "By ALEX BERENSON and JENNIFER BAYOT"}, "document_type": "article", "pub_date": "2005-05-28T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "Series", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The success stories of weight-loss surgery have been numerous and widely reported. Dangerously overweight patients -- both the famous and the unknown -- have lost hundreds of pounds, shown in before and after pictures. Many overcame life-threatening weight-related diseases. And as demand soared for new types of weight-loss surgery, known as bariatric surgery, hundreds of general surgeons took quick courses and started performing the procedures. The number of doctors rose rapidly, to more than 1,300 now from a few hundred in the early 1990's.", "headline": {"main": "Other Perils of Overweight; Insurers Balk at Bariatric Operations, Citing Cost and Risks", "kicker": "Obesity Inc."}, "abstract": "Article in series Obesity Inc focuses on weight-loss surgery known as bariatric surgery, which has eliminated debilitating diseases and improved quality of life for thousands of patients, but is now threatened by malpractice lawsuits against and growing reluctance of health plans to provide coverage; American Society of Bariatric Surgery says patients and insurers spent more than $3.5 billion in 2004 for 145,000 bariatric procedures at average of $25,000 each; add complications can raise patient's costs to $100,000; some other treatments for obesity that are under development discussed; chart; photos (M)", "print_page": "1", "word_count": 1447, "_id": "4fd247908eb7c8105d7e395a", "snippet": "The threat of malpractice lawsuits against doctors and hospitals is creating difficulties for people who want to undergo weight-loss surgery.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/05/27/business/27bariatric.html", "multimedia": [{"url": "images/2005/05/27/business/27bariatic.751.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2005/05/27/business/27bariatic.751.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "organizations", "value": "AMERICAN SOCIETY OF BARIATRIC SURGERY"}, {"name": "subject", "value": "BARIATRIC SURGERY"}, {"name": "subject", "value": "INSURANCE"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "SURVEYS AND SERIES"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "SURGERY AND SURGEONS"}, {"name": "subject", "value": "WEIGHT"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MALPRACTICE"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "OBESITY"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "HOSPITALS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Milt", "rank": 1, "lastname": "FREUDENHEIM"}], "original": "By MILT FREUDENHEIM"}, "document_type": "article", "pub_date": "2005-05-27T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "Editorial", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "It's been an up and down month for statins, a class of widely touted ''wonder drugs'' that have already sprinted to the top of the best-seller list based on their ability to lower cholesterol and thus reduce the risk of heart disease. Now preliminary studies suggest that they may be effective against an array of cancers as well, though that is far from proved. The hitch is lingering safety concerns, highlighted by a recent study showing that the most powerful drug in the class had a much higher rate of serious adverse reports than did its competitors.", "headline": {"main": "Wonder Drugs and Their Side Effects", "kicker": "Editorial"}, "abstract": "Editorial says new studies suggest that statins, which are undeniably good at lowering cholesterol, may also reduce risks of various cancers; says rigorous controlled trials are clearly needed; cites possibly dangerous side effects that have prompted some to call for removal of one, Crestor, from market", "print_page": "22", "word_count": 308, "_id": "4fd25e018eb7c8105d80d1d6", "snippet": "It's been an up and down month for statins, a class of widely touted \"wonder drugs\" that have already sprinted to the top of the best-seller list.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/05/27/opinion/27fri3.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "HEART"}, {"name": "subject", "value": "EDITORIALS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "CRESTOR (DRUG)"}, {"name": "subject", "value": "STATINS (CHOLESTEROL-LOWERING DRUGS)"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "CHOLESTEROL"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}], "byline": null, "document_type": "article", "pub_date": "2005-05-27T00:00:00Z", "section_name": "Health; Opinion"}], "meta": {"hits": 3, "offset": 0, "time": 34}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}